Analysts Set BioNTech SE (NASDAQ:BNTX) Price Target at $142.72

Shares of BioNTech SE (NASDAQ:BNTX) have earned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $143.65.

Several brokerages have weighed in on BNTX. BMO Capital Markets raised their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday. Berenberg Bank started coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price on the stock. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Finally, Wells Fargo & Company began coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp increased its stake in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares during the period. Planning Capital Management Corp increased its position in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. Quintet Private Bank Europe S.A. raised its stake in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares in the last quarter. Allianz SE purchased a new position in shares of BioNTech during the 4th quarter worth approximately $90,000. Finally, GAMMA Investing LLC lifted its holdings in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after buying an additional 300 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Down 6.6 %

Shares of BNTX opened at $98.39 on Friday. The firm has a market capitalization of $23.59 billion, a P/E ratio of -46.85 and a beta of 0.30. The firm has a fifty day moving average price of $116.45 and a 200-day moving average price of $113.13. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the business posted $1.90 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities research analysts expect that BioNTech will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.